Caricamento...

An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer

Twenty-one percent of all human cancers bear constitutively activating mutations in the proto-oncogene KRAS. This incidence is substantially higher in some of the most inherently therapy-resistant cancers including 30% of non-small cell lung cancers (NSCLC), 50% of colorectal cancers, and 95% of pan...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Discov
Autori principali: von Karstedt, Silvia, Walczak, Henning
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078304/
https://ncbi.nlm.nih.gov/pubmed/32194994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41420-020-0249-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !